Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT +7.69% Cyclically Adjusted PB Ratio is 2.80 as of Jul. 28, 2026, which is 5% below its 10-year median of 2.95. The stock has 8 warning signs investors should review. Among 356 Healthcare Providers & Services companies, Resonance Health ranks worse than 64.04% on this metric.
The historical rank and industry rank for Resonance Health's Cyclically Adjusted PB Ratio or its related term are showing as below:
ASX:RHT'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.7 Med: 2.95 Max: 26.5
Current: 2.52
During the past 13 years, Resonance Health's highest Cyclically Adjusted PB Ratio was 26.50. The lowest was 1.70. And the median was 2.95.
ASX:RHT's Cyclically Adjusted PB Ratio is ranked worse than 64.04% of 356
companies
in the Healthcare Providers & Services industry
Industry Median: 1.83
vs ASX:RHT: 2.52
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Resonance Health's adjusted book value per share data of for the fiscal year that ended in Jun25 was A$0.020. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is A$0.02 for the trailing ten years ended in Jun25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Resonance Health (ASX:RHT) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Resonance Health Cyclically Adjusted PB Ratio Related Terms
Resonance Health Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Resonance Health's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health Cyclically Adjusted PB Ratio Chart
ASX:RHT vs VEEV, BTSG, HQY: Cyclically Adjusted PB Ratio Comparison
For the Health Information Services subindustry, Resonance Health's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Cyclically Adjusted PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Resonance Health's Cyclically Adjusted PB Ratio falls into.
Resonance Health Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Resonance Health's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 2.80 mean?
Resonance Health (ASX:RHT) has a Cyclically Adjusted PB Ratio of 2.80 as of Jul. 28, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Resonance Health and its competitors. This is near median its historical median of 2.95. Over the past decade, Resonance Health's Cyclically Adjusted PB Ratio has ranged from 1.70 to 26.50. According to the industry distribution chart, Resonance Health ranks #228 out of 356 companies in the Healthcare Providers & Services industry, placing it in the top 64%.
Is Resonance Health's Cyclically Adjusted PB Ratio too high?
Resonance Health's current Cyclically Adjusted PB Ratio of 2.80 is near median its 10-year median of 2.95. Over the past 10 years, this metric has ranged from a low of 1.70 to a high of 26.50. The Healthcare Providers & Services industry median Cyclically Adjusted PB Ratio is 1.83. Resonance Health's value of 2.80 is 53% above this industry median. Based on the distribution chart, Resonance Health ranks #228 out of 356 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does Resonance Health's Cyclically Adjusted PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #228 out of 356 companies for Cyclically Adjusted PB Ratio. This places Resonance Health in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.83. Resonance Health's value of 2.80 is 53% above this benchmark. Historically, Resonance Health's own Cyclically Adjusted PB Ratio has ranged from 1.70 to 26.50 over the past decade. While the company's 10-year median is 2.95 vs. the industry median of 1.83, Resonance Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Healthcare Providers & Services company?
The median Cyclically Adjusted PB Ratio among Healthcare Providers & Services companies is 1.83, based on 356 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current Cyclically Adjusted PB Ratio of 2.80 is 53% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median Cyclically Adjusted PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Cyclically Adjusted PB Ratio is 2.80, which is near median its own 10-year median of 2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 53.3% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 2.80, which is near median its 10-year median of 2.95 and 53% above the Healthcare Providers & Services industry median of 1.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Cyclically Adjusted PB Ratio is 2.80 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
